Sunobinop for Alcoholism
Trial Summary
Do I have to stop taking my current medications for the trial?
The trial information does not specify whether you need to stop taking your current medications. Please consult with the trial coordinators for more details.
Is Sunobinop safe for human use?
How does the drug Sunobinop differ from other treatments for alcoholism?
Sunobinop is unique because it may work as a positive allosteric modulator of the GABAB receptor, similar to COR659, which has shown potential in reducing alcohol intake by affecting the brain's response to alcohol. This mechanism is different from other treatments like acamprosate or sodium oxybate, which have different ways of helping with alcohol dependence.678910
What is the purpose of this trial?
The purpose of this study is to evaluate the efficacy of sunobinop compared to placebo on alcohol craving in subjects with moderate to severe alcohol use disorder and these subjects are seeking treatment.
Eligibility Criteria
This trial is for adults over 18 with moderate to severe alcohol use disorder who are currently seeking treatment. Participants must have had at least four heavy drinking days each week in the month before starting the trial.Inclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either sunobinop or placebo to evaluate its impact on alcohol craving
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Sunobinop
Find a Clinic Near You
Who Is Running the Clinical Trial?
Imbrium Therapeutics
Lead Sponsor
Purdue Pharma LP
Industry Sponsor
Dr. Craig Landau
Purdue Pharma LP
Chief Executive Officer since 2017
MD from Albany Medical College
Dr. Marcelo Bigal
Purdue Pharma LP
Chief Medical Officer since 2018
MD from Federal University of Rio de Janeiro